SCHEMBL667914

SCHEMBL667914

CCC(C)S(=O)(=O)NC=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 2/20 0.32
ADH1C P00326 2/20 0.32
ADH1A P07327 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490221 0.74 GRIA1 (0.33)
SCHEMBL209649 0.74
SCHEMBL605595 0.72
SCHEMBL5448562 0.70
SCHEMBL2006632 0.70 GRIA1 (0.36)
SCHEMBL605594 0.70
SCHEMBL26870066 0.70 GRIA1 (0.31)
SCHEMBL2504144 0.68 ADH1B (0.30) ADH1BADH1CADH1A
SCHEMBL1446141 0.68 GRIA1 (0.31)
SCHEMBL2554677 0.67 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9066977-B2 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components TOYAMA CHEMICAL CO., LTD. (JP) 2015-06-30 US disclosed
US-9012482-B2 Drug containing benzophenone derivative or its salt TOYAMA CHEMICAL CO., LTD. (JP) 2015-04-21 US disclosed
EP-2258361-B1 USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNFalpha INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR TOYAMA CHEMICAL CO LTD (JP) 2014-09-17 EP disclosed
EP-2266557-B1 COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS TOYAMA CHEMICAL CO LTD (JP) 2013-08-14 EP disclosed
EP-1445249-B1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-07 EP disclosed
US-20120046326-A1 DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT TOYAMA CHEMICAL CO., LTD. (JP) 2012-02-23 US disclosed
EP-1481966-B1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2011-07-20 EP disclosed
US-20110039813-A1 METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS TOYAMA CHEMICAL CO., LTD. (JP) 2011-02-17 US disclosed
US-20110020366-A1 USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF ALPHA INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR TOYAMA CHEMICAL CO., LTD. (JP) 2011-01-27 US disclosed
EP-2266557-A1 METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS Toyama Chemical Co., Ltd. (JP) 2010-12-29 EP disclosed
EP-2258361-A1 USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR Toyama Chemical Co., Ltd. (JP) 2010-12-08 EP disclosed
US-20100240891-A1 DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT TOYAMA CHEMICAL CO., LTD. (JP) 2010-09-23 US disclosed
US-7772285-B2 Benzophenone derivatives or salts thereof TOYAMA CHEMICAL CO., LTD. (JP) 2010-08-10 US disclosed
WO-2008151735-A2 HETEROCYCLICALLY SUBSTITUTED HETEROCYCLYL CARBOXYLIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2008-12-18 WO disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-20050113424-A1 Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD (JP) 2005-05-26 US disclosed
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SHUNICHI SHIOZAWA (JP) 2005-05-26 US disclosed
EP-1481966-A1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-12-01 EP disclosed
EP-1445249-A1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-08-11 EP disclosed
WO-2003053349-A2 INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039813-A1 METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS SSB, NR3C2, BRPF3 ADH1B 1611/4885ADH1C 1248/4885ADH1A 2460/4885
US-20050113424-A1 Novel arylamidine derivative or salt thereof SLC7A1, NAT1, NACA ADH1B 3818/4885ADH1C 1850/4885ADH1A 1592/4885
US-20100240891-A1 DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT SOST, MYD88, TRAF6 ADH1B 3006/4885ADH1C 3426/4885ADH1A 3131/4885
US-20110020366-A1 USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF ALPHA INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR TNF, NFKBIA, CHUK ADH1B 2379/4885ADH1C 1283/4885ADH1A 2504/4885
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SP1, AP1G1, JUN ADH1B 3021/4885ADH1C 2423/4885ADH1A 1532/4885
US-20120046326-A1 DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT SOST, MYD88, TRAF6 ADH1B 3006/4885ADH1C 3426/4885ADH1A 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.